Quantitative [123]I-Ioflupane DaTSCAN single-photon computed tomography-computed tomography in Parkinsonism.

Area of Science:

• Neuroimaging
• Nuclear Medicine
• Radiopharmacology

Background:

• [123]I-Ioflupane (DaTSCAN) targets dopamine transporter (DAT) and serotonin transporter (SERT).
• Accurate quantification of striatal and extra-striatal uptake is crucial for diagnosing neurodegenerative conditions.
• Existing SPECT imaging methods may have limitations in image quality and quantification accuracy.

Purpose of the Study:

• To develop a novel method for quantifying absolute uptake in striatal (DAT-rich) and extra-striatal (SERT-rich) regions using DaTSCAN SPECT-CT.
• To enhance the image quality of DaTSCAN SPECT scans.
• To assess the correlation between different quantification metrics and body weight.

Main Methods:

• Prospective study of 26 Parkinsonism patients undergoing DaTSCAN SPECT-CT.
• Visual analysis by two independent reporters.
• Quantification using Specific Binding Ratios (SBRs) and Normalized Specific Uptake (NSU) with advanced image correction techniques.

Main Results:

• Striatal NSU and SBR showed a strong positive correlation (R=0.65-0.88, P=0.00).
• DaTSCAN SPECT-CT differentiated between normal and abnormal scans based on SBR, normalized concentrations, and NSU.
• Inverse correlation observed between body weight and normalized concentrations in extra-striatal regions and caudate nuclei.
• Both reporters confirmed improved visual quality of SPECT-CT compared to SPECT alone.

Conclusions:

• DaTSCAN SPECT-CT enables more accurate and absolute quantification of DAT and SERT binding, particularly in extra-striatal regions.
• The improved image quality enhances diagnostic potential.
• Further research is needed to establish the clinical value for diagnosing and monitoring neurodegenerative diseases and exploring the role of DAT/SERT in obesity.